Communiqués Magenta Therapeutics

Actions

MGTA

US55910K1088

Temps réel estimé Cboe BZX Autres places de cotation 16:18:52 17/07/2026			Varia. 5j.	Varia. 1 janv.
99,18 ^USD	+4,02 %		-4,68 %	+778,94 %

11/09/23	Dianthus Therapeutics, Inc. a finalisé l'acquisition de Magenta Therapeutics, Inc. (NasdaqGM:MGTA) auprès d'un groupe d'actionnaires dans le cadre d'une opération de fusion inversée.	CI
03/08/23	Magenta Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI

Communiqués

07/08/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
04/05/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
03/05/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
03/05/23	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement	AQ
06/04/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement (form 8-K)	AQ
31/03/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
31/03/23	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan	AQ
23/03/23	MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
07/02/23	MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)	AQ
02/02/23	MAGENTA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
02/02/23	Magenta Therapeutics to Explore Strategic Alternatives	AQ
25/01/23	MAGENTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
25/01/23	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety	AQ
20/12/22	MAGENTA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/12/22	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial	AQ
13/12/22	Magenta Therapeutics : Update on MGTA-117 Presentation	PU
13/12/22	MAGENTA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/12/22	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates	AQ
12/12/22	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial	AQ
03/11/22	MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
03/11/22	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights	AQ
03/11/22	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting	AQ
01/11/22	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference	AQ
17/08/22	Magenta Therapeutics : Appoints Michael Vasconcelles, M.D. to the Board of Directors - Form 8-K	PU
17/08/22	MAGENTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ